Assessment of the impact of a memory enhancer traditional oral formulation in management of dementia, a randomized controlled clinical trial.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191212045709N3

Enrollment

Registered

2020-11-14

Start date

2019-07-23

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

alzheimer disease. Other degenerative disorders of nervous system in diseases classified elsewhere

Interventions

Intervention 1: Intervention group: take 4 capsules daily, including pepper (one part), black cumin (one part) and sugar (3 parts) along with underlying drugs to control Alzheimer's for 6 months. The

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: diagnosis of dementia based on DSM criteria

Exclusion criteria

Exclusion criteria: patients with cardiovascular disease pregnancy breast feeding sensitivity to herbal medicines present in formulation patients with depression patients with peptic ulcer disease

Design outcomes

Primary

Measure	Time frame
TSH serum level. Timepoint: every 6 months. Method of measurement: serum sample.;B12 serum level. Timepoint: every 6 months. Method of measurement: serum sample.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Mehdi Zarshenas

Shiraz University of Medical Sciences

ZARM@SUMS.AC.IR+98 910 700 1164

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026